BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/13/2022 7:31:00 AM | Browse: 291 | Download: 884
 |
Received |
|
2022-01-10 16:08 |
|
Peer-Review Started |
|
2022-01-10 16:10 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-08 21:30 |
|
Revised |
|
2022-03-18 10:23 |
|
Second Decision |
|
2022-06-10 03:03 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-06-17 21:23 |
|
Articles in Press |
|
2022-06-17 21:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-06-27 00:59 |
|
Publish the Manuscript Online |
|
2022-07-13 07:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Francesco Bellanti, Aurelio Lo Buglio, Michał Dobrakowski, Aleksandra Kasperczyk, Sławomir Kasperczyk, Palok Aich, Shivaram P Singh, Gaetano Serviddio and Gianluigi Vendemiale |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Bellanti, MD, PhD, Associate Professor, Department of Medical and Surgical Sciences, University of Foggia, viale Pinto, 1, Foggia 71122, Italy. francesco.bellanti@unifg.it |
| Key Words |
Sodium glucose cotransporter-2 inhibitors; Non-alcoholic fatty liver disease; Oxidative stress; Type 2 diabetes; Liver fibrosis; Inflammation |
| Core Tip |
Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder, and it is often associated with type 2 diabetes mellitus (T2DM). Diabetic patients often suffer from advanced NAFLD and are keen on progressing toward severe fibrosis and end-stage liver disease. There is no approved treatment for NAFLD, but new drug classes introduced to treat T2DM can exert favorable effects beyond glucose control. This pilot study demonstrates that treatment with sodium glucose cotransporter-2 inhibitors in patients with T2DM and NAFLD is associated with improving liver steatosis and fibrosis markers and circulating pro-inflammatory and redox status. |
| Publish Date |
2022-07-13 07:31 |
| Citation |
Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i26/3243.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i26.3243 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
